###begin article-title 0
###xml 32 56 32 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 32 56 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
The ATM-related Tel1 protein of Saccharomyces cerevisiae controls a checkpoint response following phleomycin treatment
###end article-title 0
###begin p 1
###xml 95 125 95 125 <email xmlns:xlink="http://www.w3.org/1999/xlink">j46036a@nucc.cc.nagoya-u.ac.jp</email>
To whom correspondence should be addressed. Tel: +81 52 789 2593; Fax: +81 52 789 2589; Email: j46036a@nucc.cc.nagoya-u.ac.jp
###end p 1
###begin p 2
Present address: Toshiyasu Shimomura, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Tsukuba 300-2611, Japan
###end p 2
###begin p 3
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 72 96 72 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 534 538 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 566 570 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 666 670 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 955 959 943 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1003 1007 987 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1113 1117 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 66 71 <span type="species:ncbi:4932">yeast</span>
###xml 72 96 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
MEC1 and TEL1 encode ATR- and ATM-related proteins in the budding yeast Saccharomyces cerevisiae, respectively. Phleomycin is an agent that catalyzes double-strand breaks in DNA. We show here that both Mec1 and Tel1 regulate the checkpoint response following phleomycin treatment. MEC1 is required for Rad53 phosphorylation and cell-cycle progression delay following phleomycin treatment in G1, S or G2/M phases. The tel1Delta mutation confers a defect in the checkpoint responses to phleomycin treatment in S phase. In addition, the tel1Delta mutation enhances the mec1 defect in activation of the phleomycin-induced checkpoint pathway in S phase. In contrast, the tel1Delta mutation confers only a minor defect in the checkpoint responses in G1 phase and no apparent defect in G2/M phase. Methyl methanesulfonate (MMS) treatment also activates checkpoints, inducing Rad53 phosphorylation in S phase. MMS-induced Rad53 phosphorylation is not detected in mec1Delta mutants during S phase, but occurs in tel1Delta mutants similar to wild-type cells. Finally, Xrs2 is phosphorylated after phleomycin treatment in a TEL1-dependent manner during S phase, whereas no significant Xrs2 phosphorylation is detected after MMS treatment. Together, our results support a model in which Tel1 contributes to checkpoint control in response to phleomycin-induced DNA damage in S phase.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c1">1</xref>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c2">2</xref>
The genomes of eukaryotic cells are under continuous assault from extracellular genotoxic agents and the byproducts of intracellular processes including DNA replication. The resulting genetic damage may cause cell death or genetic instability that can lead to cancer. To ensure the proper response to genetic damage, cells have employed a set of surveillance mechanisms termed checkpoint controls (1,2).
###end p 5
###begin p 6
###xml 185 188 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 200 203 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATR</italic>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 221 245 221 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 254 266 254 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S.cerevisiae</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad3</italic>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>+</italic></sup>
###xml 276 301 276 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Schizosaccharomyces pombe</italic>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c2">2</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c3">3</xref>
###xml 845 846 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c4">4</xref>
###xml 847 848 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 221 245 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 254 266 <span type="species:ncbi:4932">S.cerevisiae</span>
###xml 276 301 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
Checkpoint pathways are an evolutionarily conserved feature of eukaryotic cells. This conservation is exemplified by the family of genes encoding high molecular weight protein kinases: ATM (mammals), ATR (mammals), MEC1 (Saccharomyces cerevisiae), TEL1 (S.cerevisiae), rad3+ (Schizosaccharomyces pombe) (2,3). Each of these gene products falls into two family groups based on homology; ATM is homologous to Tel1, while ATR is more related to Mec1 and Rad3. This homology is not restricted to the kinase domain at the C-terminus, but rather extends over the length of the protein. The C-terminal kinase domain is structurally related to the catalytic domain of the PI-3 kinases. Despite this similarity, none of these proteins has been shown to phosphorylate lipids. Instead, all these proteins are capable of phosphorylating protein substrates (4-8).
###end p 6
###begin p 7
###xml 21 33 21 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S.cerevisiae</italic>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c1">1</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c9">9</xref>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c10">10</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c11">11</xref>
###xml 304 311 304 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S.pombe</italic>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c12">12</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c15">15</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c9">9</xref>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c1">1</xref>
###xml 740 741 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c9">9</xref>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD53</italic>
###xml 812 816 812 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 840 844 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c11">11</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c16">16</xref>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c17">17</xref>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c19">19</xref>
###xml 15 20 <span type="species:ncbi:4932">yeast</span>
###xml 21 33 <span type="species:ncbi:4932">S.cerevisiae</span>
###xml 304 311 <span type="species:ncbi:4896">S.pombe</span>
###xml 419 424 <span type="species:ncbi:4932">yeast</span>
In the budding yeast S.cerevisiae, MEC1 plays a critical role in checkpoint control (1,9), whereas TEL1 shares an overlapping role with MEC1 in maintaining survival after DNA damage (10,11). Mec1 physically interacts with Lcd1 (also called Ddc2 and Pie1), a protein that exhibits limited homology to the S.pombe Rad26 and mammalian ATRIP proteins (8,12-15). DNA damage responses have been well characterized in budding yeast, and consists of the G1-, S- and G2/M-phase damage checkpoints (9). Mec1 and Lcd1 function as a complex that is essential for all three DNA damage checkpoints as well as the DNA replication block checkpoint. Similar to Mec1, Rad53 plays an essential role in both the DNA damage and replication block checkpoints (1,9). RAD53 encodes a protein kinase and functions not only downstream of MEC1 but also downstream of TEL1 (11,16). Following DNA damage and replication block, the Rad53 protein is hyperphosphorylated and activated by a mechanism dependent on Mec1. Consistent with their upstream role, both Mec1 and Lcd1 are recruited to sites of DNA damage, suggesting that the Mec1-Lcd1 complex interacts with aberrant DNA structures or the DNA repair apparatus after DNA damage (17-19). Thus, the Mec1-Lcd1 complex appears to recognize DNA damage and stalled DNA replication, and transduces a checkpoint signal to Rad53.
###end p 7
###begin p 8
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDC1</italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC3</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD17</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD24</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c20">20</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c21">21</xref>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD17</italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD24</italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC3</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDC1</italic>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c22">22</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c23">23</xref>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD24</italic>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c24">24</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c25">25</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c17">17</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c18">18</xref>
###xml 50 55 <span type="species:ncbi:4932">yeast</span>
Additional DNA damage checkpoint genes in budding yeast are DDC1, MEC3, RAD9, RAD17 and RAD24. Rad9 is hyperphosphorylated following DNA damage in a MEC1- and TEL1-dependent manner, and the phosphorylated Rad9 protein binds to Rad53 and modulates its kinase activity (20,21). Genetic evidence has suggested that RAD17, RAD24, MEC3 and DDC1 operate in a common checkpoint pathway. Indeed, Ddc1, Mec3 and Rad17 interact physically with each other and function in a complex to control the DNA damage checkpoints (22). It has been proposed that Ddc1, Mec3 and Rad17 are structurally related to PCNA (23). RAD24 encodes a protein structurally related to the subunits of replication factor C which consists of the one large subunit Rfc1 and the four small subunits Rfc2, Rfc3, Rfc4 and Rfc5 (24,25). Rad24 regulates the recruitment of the Ddc1-Mec3-Rad17 complex to sites of DNA damage (17,18).
###end p 8
###begin p 9
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c3">3</xref>
###xml 123 126 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 235 238 235 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c26">26</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c27">27</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c28">28</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c29">29</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c32">32</xref>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c33">33</xref>
###xml 1329 1334 1329 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mre11</italic>
###xml 1341 1346 1337 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad50</italic>
###xml 1355 1359 1347 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">xrs2</italic>
###xml 1468 1470 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c34">34</xref>
###xml 1486 1490 1474 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1585 1589 1569 1573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1599 1601 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c10">10</xref>
###xml 1602 1604 1586 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c11">11</xref>
###xml 1622 1627 1606 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mre11</italic>
###xml 1637 1641 1617 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">xrs2</italic>
###xml 1687 1691 1663 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1724 1728 1700 1704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1744 1746 1716 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 1747 1749 1719 1721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 1821 1825 1793 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1844 1846 1816 1818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 1847 1849 1819 1821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 1869 1873 1841 1845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 208 212 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
###xml 1038 1043 <span type="species:ncbi:4932">yeast</span>
In mammals, the ATM gene has an established role in controlling the cellular responses to double-strand breaks (DSBs) (3). ATM is mutated in patients with the genetic disorder ataxia-telangiectasia (AT), and mice carrying mutations in ATM exhibit phenotypes similar to those of AT patients. AT cells exhibit chromosomal instability and defects in the cellular response to ionizing radiation at the G1, S and G2 phases. Ionizing radiation causes various types of DNA damage, among which DSBs are the most lethal. In addition, AT cells are sensitive to the anticancer drug bleomycin, which causes DSBs (26,27). To activate the checkpoint response, ATM collaborates with the Mre11-Rad50-Nbs11 complex which has been implicated in cellular responses to DSBs. Cells defective in the Nbs1 and Mre11 function shows phenotypes similar to AT cells (28). Moreover, ATM phosphorylates Nbs1 to activate the S-phase checkpoint response (29-32). Thus, ATM and the Mre11-Rad50-Nbs1 complex appear to constitute a DNA damage response pathway. In budding yeast, the Mre11-Rad50-Xrs2 complex, which is related to the mammalian Mre11-Rad50-Nbs1 complex, plays an essential role in DSB processing (33). Several lines of evidence have suggested that Tel1 and the Mre11-Rad50-Xrs2 complex also constitute a DNA damage response pathway. Cells carrying mre11Delta, rad50Delta or xrs2Delta mutations are sensitive to DNA damage, and are defective in checkpoint responses specifically to DSBs (34). Although the tel1Delta mutation alone does not confer sensitivity to DNA damage, it does enhance sensitivity of mec1 mutants (10,11). Interestingly, mre11Delta and xrs2Delta mutations exacerbate the sensitivity of mec1 mutants to similar extents as a tel1Delta mutation (35,36). Furthermore, Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner (35,36). However, whether tel1Delta mutations confer a defect in checkpoint responses remains to be fully addressed.
###end p 9
###begin p 10
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c37">37</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c38">38</xref>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 596 600 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 687 691 683 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 825 829 821 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 974 978 966 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1083 1087 1071 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 327 332 <span type="species:ncbi:4932">yeast</span>
The observation that ATM is specifically required for cellular responses to DSBs raises a possibility that Tel1 might have a similar role in the checkpoint responses following treatment with DSB-inducing agents. Phleomycin, like bleomycin, creates DSBs in DNA, but causes more significant DNA lesions than bleomycin in budding yeast (37,38). In this study, we investigated whether TEL1 is involved in the checkpoint responses to phleomycin-induced DNA damage. We show that tel1Delta mutants are defective in delaying cell-cycle progression after phleomycin treatment in S phase. Correspondingly, TEL1 is required for the phleomycin-induced Rad53 phosphorylation in S phase. In contrast, MEC1 is required for the checkpoint responses to phleomycin treatment in G1, S and G2/M phases. Consistent with the previous finding that tel1Delta mutants are not defective in the S-phase regulation following methyl methanesulfonate (MMS) treatment, Rad53 is normally phosphorylated in tel1Delta mutants after MMS treatment during S phase. Phleomycin treatment induces Xrs2 phosphorylation in a TEL1-dependent manner during S phase, whereas MMS treatment does not cause significant Xrs2 phosphorylation. These studies provide evidence that both Mec1 and Tel1 control the checkpoint responses to phleomycin-induced DNA damage.
###end p 10
###begin title 11
MATERIALS AND METHODS
###end title 11
###begin title 12
Strains, media and general methods
###end title 12
###begin p 13
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gkg252tb1">1</xref>
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rnr1</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">URA3</italic>
###xml 411 415 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRP1</italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 265 270 <span type="species:ncbi:4932">yeast</span>
Yeast strains used in this study are isogenic and listed in Table 1. The mec1-81 mutation was isolated by a synthetic lethal screen with a rnr1 mutation (T.Shimomura and K.Sugimoto, manuscript in preparation). Standard genetic techniques were used for manipulating yeast strains. Synthetic complete medium containing 0.5% casamino acids and the appropriate supplements was used to maintain selection of URA3 or TRP1 plasmids. All the culture was grown at 30degreesC.
###end p 13
###begin title 14
Plasmids and strains construction
###end title 14
###begin p 15
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 472 475 472 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 477 480 477 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlu</italic>
###xml 520 523 520 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rsr</italic>
###xml 526 529 526 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlu</italic>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 573 576 573 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rsr</italic>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c10">10</xref>
###xml 732 733 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 780 787 780 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 789 799 789 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1-KN-HA</italic>
###xml 802 810 802 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1101 1104 1101 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nhe</italic>
###xml 1106 1109 1106 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 1160 1163 1160 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nhe</italic>
###xml 1165 1168 1165 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 1232 1235 1232 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bst</italic>
###xml 1238 1241 1238 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pvu</italic>
###xml 1338 1341 1338 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bst</italic>
###xml 1344 1347 1344 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sma</italic>
###xml 1366 1368 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c39">39</xref>
###xml 1412 1419 1412 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 1457 1460 1457 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rsr</italic>
###xml 1546 1550 1546 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1602 1609 1602 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 1614 1624 1614 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1-KN-HA</italic>
###xml 1692 1699 1692 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 1725 1729 1725 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1735 1739 1731 1735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1785 1789 1777 1781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1807 1817 1799 1809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1-KN-HA</italic>
###xml 1875 1879 1867 1871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRS2</italic>
###xml 1923 1927 1915 1919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRS2</italic>
###xml 2074 2077 2066 2069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 2079 2082 2071 2074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 2113 2116 2105 2108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 2119 2122 2111 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 2195 2198 2187 2190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 2200 2203 2192 2195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 2226 2228 2218 2220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c40">40</xref>
###xml 2267 2271 2259 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRS2</italic>
###xml 2363 2367 2355 2359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">xrs2</italic>
###xml 2510 2511 2502 2503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 2518 2522 2510 2514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 2527 2534 2515 2522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">::KanMX</italic>
###xml 2591 2593 2579 2581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c41">41</xref>
To construct the N-terminal HA-tagged TEL1, the 5'-noncoding and N-terminal region of TEL1 gene were amplified by polymerase chain reaction (PCR) with the 5'-noncoding HA-TEL1 primers KS152: 5'-TACGCGTAATCTAC-3' and KS007: 5'-TAATACGACTCACTATAGGGCGA-3' or the N-terminal HA-TEL1 primers KS153: 5'-TACGCGTATCCTTATGACGTACCAGATTATGCGGAGGATCATGGGATTGTAGAAAC-3' and KS154: 5'-CTCGT CGACTCATGTGAGCTGTTCTCC-3'. YEp-TEL1-HA plasmid was constructed by a three-part ligation of the SacI-MluI treated 5'-noncoding fragment and the RsrII-MluI treated N-terminal fragment with the SacI-RsrII-linearized YEp-TEL1 (pDM198) (10). These PCRs add the same HA epitope to Tel1 at the same amino acid position from the initiation methionine as Mec1-HA (8). To construct the kinase-negative version of TEL1-HA (tel1-KN-HA), in vitro mutagenesis was performed substituting aspartic acid to alanine at 2612 and asparagine to serine at 2616 by PCR using YEp-TEL1 with the oligonucleotide primers KS807: 5'-GCAGCTAGCTCTAT CGTTGGATACATATTAGGCCTCGGTGCTAGGCACTT AAGCAATATC-3' and KS680: 5'-AGAGTCGACTTTATT CCATTAGACAACTTT-3'. The NheI-SalI fragment of YEp-TEL1-HA was replaced by a 2.1 kb NheI-SalI fragment from the PCR product, generating YEp-TEL1-KN-HA. The BstXI-PvuII fragment from YEp-TEL1-HA, which contains the N-terminal part of Tel1-HA, was cloned into the BstXI-SmaI sites of pRS306 (39), generating YIp-TEL1-HA. To construct the TEL1-HA strain, YIp-TEL1-HA was cleaved with RsrII and transformed into cells. The precise integration, which destroys the endogenous TEL1 gene, was confirmed by PCR. The tagged constructs (TEL1-HA and tel1-KN-HA) expressed appropriate-sized proteins from their own promoter. The TEL1-HA construct suppressed the mec1Delta tel1Delta double mutants similar to the wild-type TEL1 gene whereas the tel1-KN-HA construct did not. To construct the C-terminal HA-tagged XRS2, the 5'-noncoding and N-terminal region of XRS2 gene were amplified by PCR with the primers KS759: 5'-ATCGGTACCAGAGGACACC AAAGTAAATTA-3' and KS760: 5'-ATCGGATCCCTT TTCTTCTTTTGAACGTAAACT-3'. The KpnI-BamHI- treated PCR fragment and a BamHI-SalI fragment containing sequence encoding HA epitopes were cloned into the KpnI-SalI-linearized YCplac22 (40), generating YCpT-XRS2-HA. The tagged XRS2 construct expressed appropriate- sized proteins from its own promoter and complemented the xrs2 null mutation with respect to sensitivity to DNA damage. YCp-RAD53-HA, pGST-Rad53C, YEp-MEC1-HA and YEp-MEC1-KN-HA were described previously (8). The tel1Delta::KanMX strain was constructed using pFA6a-kanMX4 as described (41).
###end p 15
###begin title 16
Drug sensitivity
###end title 16
###begin p 17
###xml 243 248 <span type="species:ncbi:4932">yeast</span>
To determine colony formation ability in the presence of phleomycin, cell cultures were serially diluted, spotted on YEPD plates with or without 5 microg/ml phleomycin (Sigma). To determine cell viability in high concentrations of phleomycin, yeast cells were incubated with 50 microg/ml phleomycin. At timed intervals, cells were withdrawn and spread on YEPD medium. After incubation for 3 days, the number of colonies was counted.
###end p 17
###begin title 18
Immunoblotting analysis
###end title 18
###begin p 19
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
Protein extracts for immunoblotting were prepared and resolved by electrophoresis on SDS-polyacrylamide gels as previously described (8). To examine phosphorylation of Rad53 and Xrs2 in S phase, cells carrying YCp-RAD53-HA and YCpT-XRS2-HA, respectively, were arrested with 6 microg/ml alpha-factor for 120 min to synchronize cells in G1. Cells were then washed to remove alpha-factor and released into fresh YEPD or YEPD containing 25 microg/ml phleomycin or 0.1% MMS. To examine Rad53 phosphorylation in G1 or G2/M phase, cells carrying YCp-RAD53-HA were arrested with 6 microg/ml alpha-factor or 15 microg/ml nocodazole for 120 min in G1 or G2/M, respectively. Cells were then treated with or without 50 microg/ml phleomycin maintaining the cell-cycle arrest.
###end p 19
###begin title 20
Phleomycin-synchrony experiment
###end title 20
###begin p 21
###xml 141 143 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c25">25</xref>
###xml 584 586 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c42">42</xref>
###xml 1013 1014 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
To examine regulation of the S phase, log-phase cultures were arrested with 6 microg/ml alpha-factor for 120 min to synchronize cells in G1 (25). Cells were then washed to remove alpha-factor and released into fresh YEPD or YEPD containing 25 microg/ml phleomycin. To examine regulation of the G1-phase progression, cells were similarly arrested at G1 and incubated with 50 microg/ml phleomycin for 60 min. Cells were then washed to remove alpha-factor and phleomycin and released into fresh YEPD. Cells were withdrawn at different times and subjected to DNA flow cytometry analysis (42). To analyze the cell-cycle delay in G2/M, log-phase cultures were arrested with 15 microg/ml nocodazole for 120 min to synchronize cells in G2/M. Cells were treated with 50 microg/ml phleomycin for 60 min after arrest, and then washed to remove nocodazole and phleomycin and released into fresh YEPD. At timed intervals, cells were withdrawn and stained with 4',6-diamidino-2-phenylindole (DAPI) for microscopic examination (8).
###end p 21
###begin title 22
Immunoprecipitation and kinase assay
###end title 22
###begin p 23
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 269 271 261 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Immunoprecipitation was performed as described previously (8). For the kinase assay, immunoprecipitates were separated into equal portions for immunoblotting and kinase reaction. Kinase assay was initiated in 40 microl of kinase buffer by the addition of 10 mCi [gamma-32P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech), substrate (2 microg of GST-Rad53C and 0.6 microg of PHAS-1) and ATP to 100 microM. Reactions were terminated by addition of 5x sample buffer and boiling for 5 min. The eluted proteins were separated by SDS-PAGE and gels were dried and autoradiographed.
###end p 23
###begin title 24
RESULTS
###end title 24
###begin title 25
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
Phleomycin-induced Rad53 phosphorylation dependent on MEC1 and TEL1
###end title 25
###begin p 26
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c11">11</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c16">16</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 382 386 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 414 418 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sml1</italic>
###xml 455 459 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 490 492 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c43">43</xref>
###xml 554 558 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sml1</italic>
###xml 740 741 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f1">1</xref>
###xml 823 827 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 872 876 848 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1069 1073 1033 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1082 1086 1042 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1150 1154 1106 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1264 1268 1216 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
We investigated how Mec1 and Tel1 control cellular responses to treatment with the DSB-inducing agent phleomycin. Rad53 is modified by phosphorylation in response to DNA damage or replication block, and its phosphorylation correlates with activation of the checkpoint pathways (11,16). We first monitored Rad53 phosphorylation after phleomycin treatment in wild-type, mec1Delta and tel1Delta mutant cells. Because sml1 mutations suppress the lethality of mec1Delta but not the checkpoints (43), all the genetic experiments were performed hereafter in an sml1Delta background. Cells expressing HA-tagged Rad53 were incubated with 5 or 50 microg/ml phleomycin for 120 min, and Rad53 modification was examined by immunoblotting analysis (Fig. 1). After exposure to phleomycin, Rad53 modification was detected in wild-type and tel1Delta cells in a dosage-dependent manner. In mec1Delta cells, Rad53 modification was observed after treatment with 50 microg/ml phleomycin, but not 5 microg/ml phleomycin. The expression level of HA-tagged Rad53 was not altered in wild-type, mec1Delta or tel1Delta mutant cells (data not shown). These results suggest that mec1Delta mutants retain a residual activity to phosphorylate Rad53 in response to phleomycin treatment, and that TEL1 might be involved in activation of the checkpoint pathways after phleomycin treatment.
###end p 26
###begin title 27
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
Requirement of MEC1 and TEL1 for checkpoint response after phleomycin treatment in S phase
###end title 27
###begin p 28
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
###xml 548 552 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 653 657 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 706 710 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sml1</italic>
###xml 790 794 770 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 871 875 847 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 984 988 956 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1154 1158 1122 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1168 1172 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 11 16 <span type="species:ncbi:4932">yeast</span>
In budding yeast, DNA damage activates the checkpoint pathways in G1, S and G2/M phases. We first investigated the roles of Mec1 and Tel1 in the S-phase checkpoint response to phleomycin treatment. The S-phase checkpoint was analyzed by monitoring the DNA content of phleomycin-treated cells after release from the G1 block (Fig. 2A). When released from alpha-factor arrest and treated with 25 microg/ml phleomycin, the S-phase progression was delayed in wild-type cells as evidenced by lower rates of DNA synthesis. Compared with wild-type cells, mec1Delta mutants were slow in the S-phase progression in the absence of phleomycin, suggesting that the mec1Delta defect is not completely suppressed by the sml1Delta mutation. Phleomycin treatment further delayed the S-phase progression of mec1Delta mutants (see the cytometry profiles at 40 min after release). However, mec1Delta cells progressed through S phase faster than wild-type cells in the presence of phleomycin. Similarly, tel1Delta mutants delayed the S-phase progression, but progressed through S phase faster than wild-type cells in the presence of phleomycin. These results show that both mec1Delta and tel1Delta mutants are partially defective in the S-phase checkpoint after phleomycin treatment.
###end p 28
###begin p 29
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 104 108 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 247 248 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
###xml 340 344 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 472 476 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 621 625 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 662 666 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 818 822 786 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 867 871 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 949 953 909 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1063 1067 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1133 1137 1085 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 1142 1146 1094 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
We next compared induction of Rad53 phosphorylation by phleomycin treatment in wild-type, mec1Delta and tel1Delta cells. Cells expressing Rad53-HA were synchronized by alpha-factor and released into medium containing 25 microg/ml phleomycin (Fig. 2B). We found that Rad53 became phosphorylated within 30 min in wild-type cells. However, in mec1Delta mutants, no Rad53 phosphorylation was detected at 30 min after release. Although Rad53 phosphorylation became apparent in mec1Delta mutants at the later time points, its phosphorylation was clearly decreased as evidenced by the appearance of more weakly smeared bands in mec1Delta cells than wild-type cells. In tel1Delta cells, Rad53 phosphorylation was not detected at 30 min after release, but became apparent at 50 min after release at levels much greater than in mec1Delta cells. The phosphorylation observed in tel1Delta cells may result from the progression of cells into G2/M phase, because tel1Delta cells are proficient in Rad53 phosphorylation in response to phleomycin treatment in G2/M phase whereas mec1Delta cells are not (see below). These results indicate that both MEC1 and TEL1 are required for the S-phase checkpoint following phleomycin treatment.
###end p 29
###begin p 30
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 217 221 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 227 231 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 313 314 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c7">7</xref>
###xml 315 317 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c44">44</xref>
###xml 335 339 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 345 349 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 371 383 351 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 446 447 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f7">7</xref>
###xml 464 471 440 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 483 495 459 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 647 648 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
###xml 747 751 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 772 779 740 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 863 867 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 933 940 897 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 945 957 909 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 1037 1044 997 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 1049 1053 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1103 1115 1059 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
We further investigated the additive effect of the mec1 and tel1 mutations on the cell-cycle progression. For this purpose, we used a weak mec1 (mec1-81) allele in combination with the tel1Delta mutation, because the mec1Delta tel1Delta double mutation confers a senescent phenotype resulting in a growth defect (7,44). In contrast to mec1Delta tel1Delta double mutants, mec1-81 tel1Delta double mutants grow as well as wild-type cells (see Fig. 7). We found that mec1-81 single and mec1-81 tel1Delta double mutants were defective in the S-phase checkpoint; these mutants progressed faster than wild-type cells in the presence of phleomycin (Fig. 2A). However, it was difficult to determine the additive defect in the cell-cycle delay. Similar to mec1Delta mutants, these mec1-81 mutants were slow in the S-phase progression in the absence of phleomycin, whereas tel1Delta mutants were not. We then examined Rad53 phosphorylation in mec1-81 and mec1-81 tel1Delta double mutants. While residual Rad53 phosphorylation was observed in both mec1-81 and tel1Delta cells, no phosphorylation was detectable in mec1-81 tel1Delta double mutants. Together, these results indicate that Mec1 and Tel1 act in parallel to activate the S-phase checkpoint responses following phleomycin treatment.
###end p 30
###begin title 31
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
Involvement of MEC1 and TEL1 in the G1 damage checkpoint induced by phleomycin treatment
###end title 31
###begin p 32
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f3">3</xref>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 523 527 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 650 657 642 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 662 674 654 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 825 829 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 871 878 855 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 909 916 893 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 921 933 905 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 1037 1041 1017 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
We next investigated the G1-phase checkpoint of mec1 and tel1 mutants cells after phleomycin treatment. We first examined the delay in cell-cycle progression at the G1- to S-phase transition after DNA damage by monitoring cellular DNA content (Fig. 3A). Phleomycin treatment induced a G1-phase arrest in wild-type cells and the arrest continued for 120 min. Although mec1Delta cells exhibited delayed progression into S phase, these cells apparently progressed from G1 phase much faster than wild-type cells. We found that tel1Delta mutants were a little defective in delaying progression into S phase. We also examined the cell-cycle progression in mec1-81 and mec1-81 tel1Delta double mutants, and found that these mutants were defective in the G1 checkpoint. However, it was not determined whether the introduction of the tel1Delta mutation enhances the defect of the mec1-81 mutation. As discussed above, mec1-81 and mec1-81 tel1Delta mutants were slow in cell-cycle progression through S phase in the absence of phleomycin, whereas tel1Delta mutants were not.
###end p 32
###begin p 33
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f3">3</xref>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 300 304 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 407 411 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 498 505 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 510 522 498 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 555 559 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 668 675 648 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 751 763 731 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
We then monitored phleomycin-induced Rad53 phosphorylation in G1-arrested cells (Fig. 3B). Rad53 phosphorylation became visible in the G1-arrested mec1Delta cells, but its phosphorylation was significantly decreased compared with the wild-type cells. Although Rad53 phosphorylation was detectable in tel1Delta mutants as in wild-type cells at 120 min after phleomycin treatment, it was clearly decreased in tel1Delta mutants at 60 min after treatment. We also examined the Rad53 phosphorylation in mec1-81 and mec1-81 tel1Delta double mutants. Similar to mec1Delta cells, the phleomycin-induced Rad53 phosphorylation was detectable, but was significantly decreased in mec1-81 mutants arrested in G1. No phosphorylation was observed in the G1-arrested mec1-81 tel1Delta double mutants. Thus, as observed for the S-phase checkpoint, Mec1 and Tel1 affect Rad53 modification and cell-cycle delay in a parallel manner in G1 phase, but the role of Tel1 in delaying cell-cycle progression seems not to be pronounced in G1 phase.
###end p 33
###begin title 34
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
Effect of the mec1 and tel1 mutations on the G2/M checkpoint following phleomycin treatment
###end title 34
###begin p 35
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 170 174 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 244 245 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f4">4</xref>
###xml 390 394 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 470 474 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 489 493 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 612 616 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 626 630 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 688 689 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f4">4</xref>
###xml 760 764 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 863 867 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 910 914 874 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 998 1002 962 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
We further investigated the G2/M-phase DNA damage checkpoint in mec1 and tel1 mutant cells after phleomycin treatment. We examined the cell-cycle arrest of mec1Delta and tel1Delta cells following DNA damage by monitoring mitotic division (Fig. 4A). When cell cultures were released from nocodazole arrest after phleomycin treatment, wild-type cells showed delayed nuclear division, whereas mec1Delta proceeded through mitosis faster than wild-type cells. In contrast to mec1Delta mutants, tel1Delta mutants underwent mitosis at the same rate as wild-type cells. We also monitored Rad53 phosphorylation status in mec1Delta and tel1Delta mutant cells arrested with nocodazole in G2/M (Fig. 4B). Upon exposure to phleomycin, Rad53 became highly phosphorylated in tel1Delta mutants as well as wild-type cells. In contrast, no apparent phosphorylation was detected in mec1Delta mutants. These results indicate that MEC1 is essential for the G2/M-phase response to phleomycin-induced DNA damage, whereas TEL1 contributes little to this checkpoint.
###end p 35
###begin title 36
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 28 32 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
Effect of the mec1Delta and tel1Delta mutations on checkpoint responses after MMS treatment in S phase
###end title 36
###begin p 37
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 259 263 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 286 288 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c45">45</xref>
###xml 289 291 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c46">46</xref>
###xml 356 357 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 374 375 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 395 396 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 420 422 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c47">47</xref>
###xml 719 723 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 733 737 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 762 763 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f5">5</xref>
###xml 973 975 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c45">45</xref>
###xml 976 978 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c46">46</xref>
###xml 1089 1090 1065 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f5">5</xref>
###xml 1141 1143 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c45">45</xref>
###xml 1144 1146 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c46">46</xref>
###xml 1149 1153 1125 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1232 1236 1204 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1303 1307 1271 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1412 1416 1376 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
The above results indicate that Mec1 and Tel1 are both required for the S-phase checkpoint response after phleomycin treatment. However, it has been demonstrated that mec1Delta mutants are defective in the S-phase checkpoint induced by MMS treatment, whereas tel1Delta mutants are not (45,46). MMS is an alkylating agent and generates methylated purines (N3-methyladenine, N7-methylguanine and O6-methylguanine) in DNA (47). Thus, MMS produces primary DNA lesions that are different from those produced by phleomycin, although MMS could create DSBs secondarily at high concentrations. To further assess the function of Mec1 and Tel1 in the MMS-induced S-phase checkpoint response, we monitored Rad53 phosphorylation in mec1Delta and tel1Delta mutant cells (Fig. 5). Cells were arrested with alpha-factor, and then released from alpha-factor into medium containing 0.1% MMS. To monitor Rad53 phosphorylation, we here used a higher concentration of MMS than previously used (45,46). Under these conditions, all the cells remained in S phase for 60 min after release from the G1 arrest (Fig. 5). However, consistent with the previous findings (45,46), mec1Delta mutants underwent S-phase progression a little faster than wild-type and tel1Delta mutant cells. MMS treatment induced Rad53 phosphorylation in tel1Delta mutants as observed in wild-type cells. In contrast, no apparent phosphorylation was detectable in mec1Delta cells after the same MMS treatment. Thus, Mec1 and Tel1 respond differently to DNA damage induced by phleomycin and MMS in S phase.
###end p 37
###begin title 38
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 38 42 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
Xrs2 phosphorylation in mec1Delta and tel1Delta mutants after treatment with phleomycin or MMS during S phase
###end title 38
###begin p 39
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c33">33</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 550 554 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 758 759 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
###xml 764 765 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f5">5</xref>
###xml 927 928 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f6">6</xref>
###xml 1075 1079 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1106 1110 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1131 1132 1103 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f6">6</xref>
###xml 81 86 <span type="species:ncbi:4932">yeast</span>
Mre11, Rad50 and Xrs2 form a complex which is required for DSB repair in budding yeast (33). The Mre11-Rad50-Xrs2 complex appears to be targeted by Tel1 after DNA damage (35,36). Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner, and their phosphorylation is detectable as slowly migrating forms by immunoblotting analysis (35,36). Because Tel1 is required for the S-phase checkpoint response after phleomycin treatment but not MMS treatment, we examined the phosphorylation status of Xrs2 during S phase in mec1Delta and tel1Delta mutants. Cells expressing HA-tagged Xrs2 were arrested with alpha-factor, and then released from alpha-factor into medium containing 25 microg/ml phleomycin or 0.1% MMS as described above (see Figs 2 and 5). Xrs2 phosphorylation was observed after phleomycin treatment in wild-type cells, whereas no significant phosphorylation was detected after MMS treatment (Fig. 6). The phleomycin-induced Xrs2 phosphorylation was largely dependent on Tel1, because its phosphorylation was abolished by the introduction of the tel1Delta mutation but not the mec1Delta mutation (Fig. 6). These results are consistent with the model in which Tel1 is required for the S-phase checkpoint response after phleomycin treatment.
###end p 39
###begin title 40
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
Effect of the tel1Delta mutation on cell viability after phleomycin treatment
###end title 40
###begin p 41
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 195 202 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 256 260 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 324 325 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f7">7</xref>
###xml 332 336 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 488 492 476 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 545 552 529 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 572 573 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f7">7</xref>
###xml 604 608 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 680 684 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 714 718 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
Because both mec1 and tel1 mutants are defective in phleomycin-induced checkpoints, we examined whether the mec1 and tel1 mutations confer sensitivity to phleomycin. Cells carrying mec1Delta and mec1-81 mutations were hypersensitive to phleomycin, whereas tel1Delta mutants were no more sensitive than wild-type cells (Fig. 7). The tel1Delta mutation had no effect on cell viability after short exposure to high concentrations of phleomycin (data not shown). However, introduction of the tel1Delta mutation enhanced sensitivity to phleomycin in mec1-81 mutant cells (Fig. 7). These results indicate that MEC1 has an essential role in phleomycin-induced DNA damage repair and that TEL1 has an overlapping role with MEC1.
###end p 41
###begin title 42
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro phosphorylation by Mec1 and Tel1
###end title 42
###begin p 43
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c7">7</xref>
###xml 343 351 343 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 429 437 429 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 512 519 512 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 721 728 721 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 730 740 730 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1-KN-HA</italic>
###xml 1020 1021 1020 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 1059 1060 1059 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c7">7</xref>
###xml 1252 1260 1252 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1448 1449 1448 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f8">8</xref>
###xml 1577 1578 1577 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c7">7</xref>
###xml 1579 1580 1579 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c8">8</xref>
###xml 1631 1632 1631 1632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f8">8</xref>
Mec1 and Tel1 play a redundant role in activation of the checkpoint pathway, but Mec1 plays a more significant role than Tel1. One explanation could be that Mec1 and Tel1 have different substrate preference. It has been shown that both Mec1 and Tel1 phosphorylate PHAS-1 in vitro (7), and that Mec1 phosphorylates the C-terminal half of Rad53 in vitro (8). We first asked whether Tel1 phosphorylates the C-terminal half of Rad53 in vitro as Mec1 does. For this purpose, we generated an HA-tagged TEL1 construct (TEL1-HA). Tel1 contains the motif DXXXXN at positions 2612-2616, which plays a critical role in protein kinase catalysis. We mutated this conserved motif to AXXXXS and constructed a kinase-negative version of TEL1-HA (tel1-KN-HA). Rad53 has 16 SQ/TQ motifs; eight of them are located in the N-terminus including the kinase domain, and eight are in the C-terminus. To examine Rad53 phosphorylation, GST fusion proteins with the C-terminal half of Rad53 (GST-Rad53C) were expressed and purified from bacteria (8). PHAS-1 also contains SQ/TQ motifs (7). Extracts were prepared from cells expressing Tel1-HA, Tel1-KN-HA or no HA-tagged protein, and were immunoprecipitated with anti-HA antibodies. Immuno precipitates were then subjected to an in vitro kinase assay. GST-Rad53C and PHAS-1 were phosphorylated by the immunoprecipitates containing Tel1-HA but not by the immunoprecipitates containing Tel1-KN-HA or no HA-tagged protein (Fig. 8A). No specific phosphorylation of GST alone was observed with Tel1-HA (data not shown). Consistent with the previous findings (7,8), Mec1 phosphorylated GST-Rad53C and PHAS-1 (Fig. 8A). Our analysis, however, does not exclude the possibility that Mec1 and Tel1 phosphorylate others than SQ/TQ motifs in GST-Rad53C and PHAS-1.
###end p 43
###begin p 44
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f8">8</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f8">8</xref>
###xml 591 599 591 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
We then performed the Mec1 and Tel1 kinase assay in the presence of the same amounts of PHAS-1 and GST-Rad53C substrates. In these reactions, Mec1 phosphorylated GST-Rad53C more efficiently than Tel1 did, whereas Tel1 phosphorylated PHAS-1 more efficiently than Mec1 did (Fig. 8B). Both Tel1 and Mec1 were fused to the same HA tag at their N-termini (see Materials and Methods) and the amounts of each protein in the immunoprecipitates were estimated to be similar by immunoblotting analysis (Fig. 8B). Together, these results suggest that Mec1 and Tel1 have different substrate preferences in vitro.
###end p 44
###begin title 45
DISCUSSION
###end title 45
###begin p 46
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 751 755 751 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 894 898 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 971 975 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1205 1209 1205 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1249 1261 1249 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
###xml 1437 1445 1433 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 178 183 <span type="species:ncbi:4932">yeast</span>
In mammalian cells, both ATM and ATR have been implicated in the response to DSB-inducing ionizing radiation. Both ATR-related and ATM-related proteins are also found in budding yeast, encoded by MEC1 and TEL1, respectively. Genetic and biochemical studies have demonstrated that Mec1 plays a central role in the DNA damage checkpoint, but the function of Tel1 in checkpoints has not been well characterized. Since ATM is specifically required for checkpoint responses to DSBs, we hypothesized that Tel1 might have a similar role. In this report, we investigated the roles of Mec1 and Tel1 in the checkpoint responses to phleomycin, an agent that causes DSBs in DNA. Phleomycin, like other DNA-damaging agents, induces Rad53 phosphorylation in cells. MEC1 is required for Rad53 phosphorylation and cell-cycle arrest following phleomycin treatment in all the G1, S and G2/M phases. In contrast, TEL1 is required for Rad53 phosphorylation and cell-cycle arrest in S phase. TEL1 is as well partially required for Rad53 phosphorylation and cell-cycle arrest in G1 phase, but not in G2/M phase. Consistent with the role of Tel1 in the S-phase regulation, Xrs2 is phosphorylated after phleomycin treatment in a TEL1-dependent manner in S phase. Moreover, mec1-81 tel1Delta double mutants are more defective than either single mutants in Rad53 phosphorylation in S phase. Finally, both Mec1 and Tel1 phosphorylate the Rad53 and PHAS-1 proteins in vitro. Taken together, these results strongly suggest that both Mec1 and Tel1 control checkpoint responses to phleomycin-induced DNA damage.
###end p 46
###begin p 47
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 303 305 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c45">45</xref>
###xml 306 308 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c46">46</xref>
###xml 375 379 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 468 472 460 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
Similar to phleomycin treatment, MMS treatment activates checkpoints and induces Rad53 phosphorylation in S phase. However, mec1 and tel1 mutants behave differently in response to MMS treatment; mec1 mutants are defective in the S-phase checkpoint after MMS treatment whereas tel1Delta mutants are not (45,46). Correspondingly, MMS treatment induces Rad53 phosphorylation in tel1Delta mutants as observed in wild-type cells, but the phosphorylation is not detected in mec1Delta mutants. Together, these results support a model in which Mec1 and Tel1 regulate pathways in parallel and are activated by different types of DNA damage.
###end p 47
###begin p 48
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 146 150 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 322 326 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 511 515 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 859 863 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 934 939 918 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 942 944 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 969 973 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sae2</italic>
###xml 978 984 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad50s</italic>
Cells carrying the tel1Delta mutation are defective in delaying cell-cycle progression in S phase when DNA is damaged by phleomycin. In contrast, tel1Delta mutants are only weakly defective in the G1-phase responses and proficient in the G2/M-phase responses following phleomycin treatment. Thus, the checkpoint defect in tel1Delta mutants upon the occurrence of DSBs appears to be mainly caused by the inability to cope with DSBs in S phase. One possible explanation was that the checkpoint defect observed in tel1Delta mutants could be attributed, at least in part, to the cell-cycle-dependent expression of Mec1 and/or Tel1. However, the expression levels of both Mec1 and Tel1 are not altered during the cell cycle (data not shown). Alternatively, DSBs might be more improperly processed during S phase than G1 or G2/M phase, resulting in activation of a TEL1-dependent checkpoint response. Consistent with this possibility, Usui et al. (36) have demonstrated that sae2 and rad50s mutations, which cause a defect in DSB processing, enhance the Tel1-mediated checkpoint response.
###end p 48
###begin p 49
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c20">20</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c48">48</xref>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 688 696 688 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Rad53 is phosphorylated in response to DNA damage, and its phosphorylation is correlated with activation of the Rad53 kinase. We showed that phleomycin treatment induces Rad53 phosphorylation in a MEC1- and TEL1-dependent manner. Recent evidence has suggested that Rad53 phosphorylation following DNA damage might result entirely from increased autophosphorylation activity (20). However, DNA damage induces hyperphosphorylation of Rad53 mutant proteins which possess little autophosphorylation activity (48). Thus, after DNA damage Rad53 becomes phosphorylated in trans in a Mec1- and Tel1-dependent manner. Consistently, both Mec1 and Tel1 were found to phosphorylate the Rad53 protein in vitro.
###end p 49
###begin p 50
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 519 523 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 533 535 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c49">49</xref>
###xml 572 576 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 760 764 752 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 843 847 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1</italic>
###xml 895 899 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 950 954 934 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
It has been suggested that DNA damage accumulates more in checkpoint defective mutants than wild-type cells. Although tel1Delta mutants are defective in the S-phase checkpoint, they do not show hypersensitivity to phleomycin. One explanation could be that a functional G2/M checkpoint compensates for defects in S phase. Perhaps if the G2/M checkpoint is fully functional and activated, DNA damage might be repaired sufficiently to allow cells to remain viable. Indeed, similar phenotypes have been observed in several mec1 mutants (49); these mutants are as defective as mec1Delta in both the G1- and S-phase checkpoints following treatment with UV light and MMS, although they do not show hypersensitivity to UV or MMS. Alternatively, it is possible that in tel1Delta mutants DNA damage accumulates but might be processed efficiently by the MEC1-dependent repair pathway. Supporting this, the tel1Delta mutation was found to enhance sensitivity of mec1 mutants to phleomycin.
###end p 50
###begin p 51
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NBS1</italic>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c2">2</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c3">3</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c50">50</xref>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRE11</italic>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c51">51</xref>
###xml 455 462 455 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c30">30</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c32">32</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c33">33</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c34">34</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 931 936 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mre11</italic>
###xml 946 950 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">xrs2</italic>
###xml 1004 1008 996 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 1041 1045 1033 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 1061 1063 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 1064 1066 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 1135 1139 1123 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1</italic>
###xml 1158 1160 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 1161 1163 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 1295 1297 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c35">35</xref>
###xml 1298 1300 1286 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg252c36">36</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 586 591 <span type="species:ncbi:9606">human</span>
###xml 611 616 <span type="species:ncbi:4932">yeast</span>
The human genes mutated in AT and Nijmegen breakage syndrome, ATM and NBS1, respectively, are both involved in the cellular response to DSBs (2,3). The Nbs1 protein forms a complex with the human Mre11 and Rad50 proteins, which are implicated in DSB repair (50). Mutations in the MRE11 gene were also found in individuals with another AT-like disorder (51). Moreover, ATM directly phosphorylates Nbs1 on several sites required for its checkpoint function in vivo (30-32). These results have demonstrated a functional and biochemical link between ATM and the Mre11-Rad50-Nbs1 complex in human cells. The budding yeast Mre11- Rad50-Xrs2 complex has an established role in both non-homologous end-joining and homologous recombination repair of DSBs (33). Recently, several groups showed that the Mre11-Rad50-Xrs2 complex is required for checkpoint responses after treatment of DSB-inducing agents (34-36). It has been also shown that mre11Delta and xrs2Delta mutations enhance the DNA-damage sensitivity of mec1 mutants to similar extents as a tel1Delta mutation (35,36). Moreover, Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner (35,36). These findings have suggested the model in which Tel1 and the Mre11-Rad50-Xrs2 complex constitute a DNA damage response pathway (35,36). We have shown that Tel1 is required for Xrs2 phosphorylation as well as checkpoint responses after phleomycin treatment in S phase. Our results extend the notion that the Mre11-Rad50-Nbs1/Xrs2 complex and ATM family protein are structurally and functionally conserved in eukaryotes.
###end p 51
###begin title 52
Figures and Tables
###end title 52
###begin p 53
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 29 33 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 115 119 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 139 143 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
 Effect of the mec1Delta and tel1Delta mutations on phleomycin-induced Rad53 phosphorylation. Wild-type (KSC1178), mec1Delta (KSC1186) and tel1Delta (KSC1368) cells carrying YCp-RAD53-HA were untreated or treated with 5 or 50 microg/ml phleomycin for 120 min. Cell extracts were then subjected to immunoblotting analysis with anti-HA antibodies as described in Materials and Methods.
###end p 53
###begin p 54
###xml 62 63 62 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 592 593 580 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 929 933 909 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 950 954 926 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 971 978 943 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 993 1005 965 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
 Checkpoint responses after phleomycin treatment in S phase. (A) The S-phase checkpoint response to phleomycin. Cells were synchronized with alpha-factor in G1 and released in either the presence or the absence of 25 microg/ml phleomycin (PM). Aliquots of cells were collected at the indicated times after release from alpha-factor treatment and subjected to flow cytometric analyses as described in Materials and Methods. Dotted lines indicate the DNA content of 1C and 2C cells. The top panels represent asynchronous (As) cells not treated with phleomycin and are included as a reference. (B) Kinetics of Rad53 phosphorylation after release from G1 arrest into phleomycin. Cells carrying YCp-RAD53-HA were arrested in G1 with alpha-factor and released in medium containing 25 microg/ml phleomycin as in (A). Cells were harvested at time indicated and subjected to immunoblotting analysis. Strains used are wild-type (KSC1178), mec1Delta (KSC1186), tel1Delta (KSC1368), mec1-81 (KSC1400) and mec1-81 tel1Delta (KSC1402).
###end p 54
###begin p 55
###xml 63 64 63 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 496 497 480 481 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 810 814 786 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 831 835 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 852 859 820 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 871 883 839 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
 Checkpoint responses after phleomycin treatment in G1 phase. (A) Cell-cycle progression at the G1/S transition after phleomycin treatment. Cells were synchronized with alpha-factor in G1 and further treated with 50 microg/ml phleomycin for 60 min, and then released from alpha-factor and phleomycin into YEPD as described in Materials and Methods. Aliquots of cells were collected at the indicated times after release from alpha-factor treatment and examined for DNA content by flow cytometry. (B) Rad53 phosphorylation after phleomycin treatment in G1 phase. Cells carrying YCp-RAD53-HA were arrested in G1 with alpha-factor and untreated or treated with 50 microg/ml phleomycin for 60 or 120 min maintaining the G1 arrest and then subjected to immunoblotting analysis. Strains used are wild-type (KSC1178), mec1Delta (KSC1186), tel1Delta (KSC1368), mec1-81 (KSC1400), mec1-81 tel1Delta (KSC1402).
###end p 55
###begin p 56
###xml 65 66 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 432 433 428 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 791 795 783 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 815 819 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
 Checkpoint responses after phleomycin treatment in G2/M phase. (A) Cell-cycle progression in G2/M phase after phleomycin treatment. Cells were synchronized with nocodazole in G2/M and further treated with 50 microg/ml phleomycin for 60 min. At the indicated times after release of phleomycin-treated (+PM) and untreated (-PM) cultures from nocodazole, the percentage of uninucleate large budded cells was scored by DAPI staining. (B) Rad53 phosphorylation after phleomycin treatment in G2/M. Cells carrying YCp-RAD53-HA were arrested in G2/M with nocodazole and untreated or treated with 50 microg/ml phleomycin maintaining the cell-cycle arrest. Cells collected at the indicated time were subjected to immunoblotting analysis with anti-HA antibodies. Strains used are wild-type (KSC1178), mec1Delta (KSC1186) and tel1Delta (KSC1368).
###end p 56
###begin p 57
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 29 33 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 123 127 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 147 151 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 275 276 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
###xml 409 410 385 386 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 442 443 418 419 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 458 459 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
 Effect of the mec1Delta and tel1Delta mutations on the MMS-induced Rad53 phosphorylation in S phase. Wild-type (KSC1178), mec1Delta (KSC1186) and tel1Delta (KSC1368) cells carrying YCp-RAD53-HA were synchronized with alpha-factor in G1 and released in 0.1% MMS as in Figure 2. Aliquots of cells were collected at the indicated times after release from alpha-factor treatment and subjected to immunoblotting (A) and flow cytometric analyses (B) as in Figure 2.
###end p 57
###begin p 58
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 29 33 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 141 145 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 165 169 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 322 323 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg252f2">2</xref>
 Effect of the mec1Delta and tel1Delta mutations on Xrs2 phosphorylation after phleomycin and MMS treatment in S phase. Wild-type (KSC1178), mec1Delta (KSC1186) and tel1Delta (KSC1368) cells carrying YCpT-XRS2-HA were synchronized with alpha-factor in G1 and released into 25 microg/ml phleomycin or 0.1% MMS as in Figure 2. Aliquots of cells were collected at the indicated times after release from alpha-factor treatment and subjected to immunoblotting.
###end p 58
###begin p 59
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 111 115 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 132 139 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81</italic>
###xml 151 163 143 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1-81 tel1</italic>
 Effect of the mec1 and tel1 mutations on sensitivity to phleomycin. Wild-type (KSC1178), mec1Delta (KSC1186), tel1Delta (KSC1368), mec1-81 (KSC1400), mec1-81 tel1Delta (KSC1402) cells were grown to log phase and cell cultures were serially diluted, spotted on the YEPD plates with or without 5 microg/ml phleomycin.
###end p 59
###begin p 60
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mec1</italic>
###xml 261 265 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tel1</italic>
###xml 725 727 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 954 955 946 947 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1024 1031 1016 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MEC1-HA</italic>
###xml 1043 1050 1035 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL1-HA</italic>
###xml 1177 1179 1161 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
 Protein kinase activity associated with Mec1 and Tel1. (A) In vitro phosphorylation of Rad53 and PHAS-1 by Mec1 and Tel1. Extracts were prepared from mec1Delta cells (KSC1186) carrying YEp-MEC1-HA, YEp-MEC1-KN-HA, or the control vector (left columns), or from tel1Delta (KSC1368) cells carrying YEp-TEL1-HA, YEp-TEL1-KN-HA or the control vector (right columns). Cells were grown to the mid-log phase and harvested for preparation of crude extracts. Extracts were subjected to immunoprecipitation with anti-HA antibodies. The immunoprecipitated HA-tagged Mec1 and Tel1 proteins were assayed for kinase activity using GST-Rad53C or PHAS-1 as a substrate as described in Materials and Methods. In each of the top three panels, 32P incorporation into GST-Rad53C or PHAS-1 was detected by autoradiography. In each of the bottom panels, the amount of the Mec1 or Tel1 protein used for the kinase assay was examined by immunoblotting with anti-HA antibodies. (B) Substrate preference of Mec1 and Tel1. Extracts were prepared from MEC1-HA (KSC1212), TEL1-HA (KSC1517) and untagged (KSC006) cells. The kinase assay was performed with GST-Rad53C (2 microg) and PHAS-1 (0.6 microg), and 32P incorporation was detected by autoradiography. In the bottom panel, the amount of the Mec1 and Tel1 protein used for the kinase assay was examined by immunoblotting. The star indicates bands which were detectable without addition of substrate (data not shown).
###end p 60
###begin title 61
Strains used in this study
###end title 61
###begin title 62
ACKNOWLEDGEMENTS
###end title 62
###begin p 63
We thank Phil Hieter and Tomoko Ogawa for materials, Seiko Ando for plasmid construction, and Marc Lamphier for critical readings of the manuscript. This work was supported by Grant-in-Aid for Scientific Research on Priority Areas and General Research from the Ministry of Education, Science, Sports and Culture of Japan.
###end p 63
###begin title 64
REFERENCES
###end title 64

